home / stock / lbtsf / lbtsf quote
Last: | $9.51 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $9.51 |
High: | $0 |
Low: | $0 |
Volume: | 1 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.51 | $0 | $9.51 | $0 | $0 | 1 | 04-30-2024 |
$9.51 | $0 | $9.51 | $0 | $0 | 6 | 04-01-2024 |
$9.51 | $9.51 | $9.51 | $9.51 | $9.51 | 219 | 01-26-2024 |
$9.29 | $9.29 | $9.29 | $9.29 | $9.29 | 235 | 01-19-2024 |
$9.1 | $9.1 | $9.1 | $9.1 | $9.1 | 815 | 12-25-2023 |
$9.1 | $9.1 | $9.1 | $9.1 | $9.1 | 815 | 12-22-2023 |
$9.16 | $9.16 | $9.16 | $9.16 | $9.16 | 107 | 12-12-2023 |
$9 | $0 | $9 | $0 | $0 | 586 | 11-20-2023 |
$9 | $9 | $9 | $9 | $9 | 100 | 11-10-2023 |
$10.18 | $10.18 | $10.18 | $10.18 | $10.18 | 100 | 09-13-2023 |
$9.82 | $9.82 | $9.82 | $9.82 | $9.82 | 314 | 07-28-2023 |
$8.85 | $0 | $8.85 | $0 | $0 | 34 | 07-05-2023 |
$8.85 | $8.85 | $8.85 | $8.85 | $8.85 | 400 | 06-21-2023 |
$9.68 | $0 | $9.68 | $0 | $0 | 2 | 06-14-2023 |
$9.68 | $0 | $9.68 | $0 | $0 | 3 | 06-09-2023 |
$9.68 | $0 | $9.68 | $0 | $0 | 3 | 06-08-2023 |
$9.68 | $0 | $9.68 | $0 | $0 | 1 | 06-07-2023 |
$9.68 | $0 | $9.68 | $0 | $0 | 25,000 | 04-24-2023 |
$9.68 | $9.68 | $9.68 | $9.68 | $9.68 | 106 | 12-01-2022 |
$9.28 | $9.28 | $9.28 | $9.28 | $9.28 | 1,000 | 09-09-2022 |
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon re...
Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseases NN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated d...
Almirall’s Full-Year 2023 Results Company revenue growth driven by the strong performance of the European Dermatology business (+17% year-on-year) based on key growth divers and new launches: Ilumetri ® growing sales at 33.5% year-on-year; Klisyri ® strong sales g...